Vrije Universiteit Brussel
A new adoptive T-cell therapy targeting B7-H3 and HMGB1: towards a cure for multiple myeloma
2022
Elsene
Project gerealiseerd door Yannick De Vlaeminck, ondersteund door de Fondsen Catharina Weekers, Raymond Wuyts, Arlette Lemaître, Yvette Gembauve & Cambier-Sandra.
Multiple myeloma (MM) treatment with T cells engineered to express chimeric antigen receptors (CARs) shown promising responses yet with room for improvement. Therefore, we propose to develop B7-H3 nanoCAR-T cells that produce HMGB1-blocking peptides allowing us to study simultaneously the novel B7-H3 target and recently identified immune suppressor HMGB1, thereby enhancing the functionality of the CAR-T therapy. If successful, the results of this project can be translated to the clinic.